Published in JAMA on November 07, 2001
Brain Imaging and Mental Disorders of Aging Intervention | NCT00267163
Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement (2005) 7.90
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A (2003) 6.46
Functional deactivations: change with age and dementia of the Alzheimer type. Proc Natl Acad Sci U S A (2003) 5.64
Relationships between biomarkers in aging and dementia. Neurology (2009) 4.16
Epidemiology of Alzheimer disease. Nat Rev Neurol (2011) 4.13
Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging (2005) 3.32
Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A (2005) 3.02
The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 2.86
Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage (2009) 2.80
Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med (2010) 2.77
Longitudinal change of biomarkers in cognitive decline. Arch Neurol (2011) 2.51
FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging (2009) 2.15
Adjustment for selection bias in observational studies with application to the analysis of autopsy data. Neuroepidemiology (2009) 2.11
Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol Genomics (2008) 2.11
Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. Biol Psychiatry (2008) 1.93
Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging (2007) 1.90
Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain (2011) 1.89
Biomarkers for early detection of Alzheimer pathology. Neurosignals (2007) 1.86
Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol (2014) 1.86
Posterior cingulate glucose metabolism, hippocampal glucose metabolism, and hippocampal volume in cognitively normal, late-middle-aged persons at 3 levels of genetic risk for Alzheimer disease. JAMA Neurol (2013) 1.75
Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs (2010) 1.72
Random forest-based similarity measures for multi-modal classification of Alzheimer's disease. Neuroimage (2012) 1.71
Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann N Y Acad Sci (2008) 1.64
The Alzheimer's disease mitochondrial cascade hypothesis. J Alzheimers Dis (2010) 1.60
Large-scale functional brain network abnormalities in Alzheimer's disease: insights from functional neuroimaging. Behav Neurol (2009) 1.58
Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. NeuroRx (2005) 1.58
Apolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging. J Neurosci (2012) 1.58
Critical role of soluble amyloid-β for early hippocampal hyperactivity in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2012) 1.58
Multivariate and univariate analysis of continuous arterial spin labeling perfusion MRI in Alzheimer's disease. J Cereb Blood Flow Metab (2007) 1.50
Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol (2008) 1.49
Covariance PET patterns in early Alzheimer's disease and subjects with cognitive impairment but no dementia: utility in group discrimination and correlations with functional performance. Neuroimage (2004) 1.49
Cellular metabolic and autophagic pathways: traffic control by redox signaling. Free Radic Biol Med (2013) 1.46
Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's disease. Alzheimers Dement (2011) 1.41
Alzheimer's disease and mild cognitive impairment. Neurol Clin (2007) 1.39
The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. Biochim Biophys Acta (2013) 1.34
Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis (2010) 1.28
Reduced glutamate neurotransmission in patients with Alzheimer's disease -- an in vivo (13)C magnetic resonance spectroscopy study. MAGMA (2003) 1.26
Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J Geriatr Psychiatry Neurol (2010) 1.24
Where the brain grows old: decline in anterior cingulate and medial prefrontal function with normal aging. Neuroimage (2007) 1.21
Covarying alterations in Aβ deposition, glucose metabolism, and gray matter volume in cognitively normal elderly. Hum Brain Mapp (2012) 1.17
Quantification of cerebral glucose metabolic rate in mice using 18F-FDG and small-animal PET. J Nucl Med (2009) 1.17
Translational research in central nervous system drug discovery. NeuroRx (2005) 1.12
Biomarkers in translational research of Alzheimer's disease. Neuropharmacology (2010) 1.11
Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. Eur J Nucl Med Mol Imaging (2012) 1.10
Advances in neuroimaging of traumatic brain injury and posttraumatic stress disorder. J Rehabil Res Dev (2009) 1.08
Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies. J Clin Neurol (2009) 1.06
Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer's disease. Neurobiol Aging (2011) 1.06
Functional expression of SGLTs in rat brain. Am J Physiol Cell Physiol (2010) 1.04
Effects of age on the glucose metabolic changes in mild cognitive impairment. AJNR Am J Neuroradiol (2010) 1.04
Ushering in the study and treatment of preclinical Alzheimer disease. Nat Rev Neurol (2013) 1.03
Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET. Eur J Nucl Med Mol Imaging (2005) 1.03
Insulin-resistant brain state: the culprit in sporadic Alzheimer's disease? Ageing Res Rev (2011) 1.03
Hypometabolism in Alzheimer-affected brain regions in cognitively healthy Latino individuals carrying the apolipoprotein E epsilon4 allele. Arch Neurol (2010) 1.02
Multi-region analysis of longitudinal FDG-PET for the classification of Alzheimer's disease. Neuroimage (2012) 1.00
Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. Neuroimage Clin (2013) 0.99
The energy-redox axis in aging and age-related neurodegeneration. Adv Drug Deliv Rev (2009) 0.98
Higher serum glucose levels are associated with cerebral hypometabolism in Alzheimer regions. Neurology (2013) 0.98
Brain imaging in the study of Alzheimer's disease. Neuroimage (2011) 0.97
Bioenergetic flux, mitochondrial mass and mitochondrial morphology dynamics in AD and MCI cybrid cell lines. Hum Mol Genet (2013) 0.96
Effects of chronic alcohol dependence and chronic cigarette smoking on cerebral perfusion: a preliminary magnetic resonance study. Alcohol Clin Exp Res (2006) 0.96
Relationship between baseline brain metabolism measured using [¹⁸F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease. Brain Imaging Behav (2012) 0.96
Fluorodeoxyglucose-positron emission tomography in the differential diagnosis of early-onset dementia: a prospective, community-based study. BMC Neurol (2009) 0.95
PET-based molecular imaging in neuroscience. Eur J Nucl Med Mol Imaging (2003) 0.95
Alzheimer's disease: a clinical practice-oriented review. Front Neurol (2012) 0.95
What we need to know about age related memory loss. BMJ (2002) 0.94
Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients. J Nucl Med (2011) 0.94
Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. NeuroRx (2005) 0.94
Neuroimaging of individuals with Down's syndrome at-risk for dementia: evidence for possible compensatory events. Neuroimage (2007) 0.93
Glucose metabolism during resting state reveals abnormal brain networks organization in the Alzheimer's disease and mild cognitive impairment. PLoS One (2013) 0.93
Feature selection using factor analysis for Alzheimer's diagnosis using 18F-FDG PET images. Med Phys (2010) 0.93
Bioenergetic medicine. Br J Pharmacol (2014) 0.93
Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC. J Neurol Neurosurg Psychiatry (2003) 0.93
Initial experience in using continuous arterial spin-labeled MR imaging for early detection of Alzheimer disease. AJNR Am J Neuroradiol (2010) 0.92
Glucose metabolism in normal aging and Alzheimer's disease: Methodological and physiological considerations for PET studies. Clin Transl Imaging (2013) 0.91
Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment. Brain (2014) 0.91
Apolipoprotein E genotype modifies the association between midlife lung function and cognitive function in old age. Dement Geriatr Cogn Disord (2009) 0.91
Positron emission tomography scans obtained for the evaluation of cognitive dysfunction. Semin Nucl Med (2008) 0.90
Early detection of Alzheimer's disease with PET imaging. Neurodegener Dis (2010) 0.90
What have novel imaging techniques revealed about metabolism in the aging brain? Future Neurol (2014) 0.89
White matter lesion load is associated with resting state functional MRI activity and amyloid PET but not FDG in mild cognitive impairment and early Alzheimer's disease patients. J Magn Reson Imaging (2013) 0.89
Molecular neuroimaging in Alzheimer's disease. NeuroRx (2004) 0.88
Longitudinal progression of cognitive decline correlates with changes in the spatial pattern of brain 18F-FDG PET. J Nucl Med (2013) 0.87
Evolution of the diagnostic criteria for degenerative and cognitive disorders. Curr Opin Neurol (2011) 0.86
Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments. Neurobiol Aging (2011) 0.86
Applications of positron emission tomography (PET) in neurology. J Neurol Neurosurg Psychiatry (2004) 0.86
FDG- and amyloid-PET in Alzheimer's disease: is the whole greater than the sum of the parts? Q J Nucl Med Mol Imaging (2011) 0.86
A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis. Biomed Res Int (2014) 0.85
Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals. BMC Med (2012) 0.85
Correlation of brain amyloid with "aerobic glycolysis": A question of assumptions? Proc Natl Acad Sci U S A (2010) 0.85
Arterial spin labeled MRI in prodromal Alzheimer's disease: A multi-site study. Neuroimage Clin (2013) 0.84
Motion compensation for brain PET imaging using wireless MR active markers in simultaneous PET-MR: phantom and non-human primate studies. Neuroimage (2014) 0.84
A new integrative model of cerebral activation, deactivation and default mode function in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2008) 0.84
Brain: normal variations and benign findings in fluorodeoxyglucose-PET/computed tomography imaging. PET Clin (2014) 0.84
Brain PET in the diagnosis of Alzheimer's disease. Clin Nucl Med (2014) 0.84
(99m)Tc hexamethyl-propylene-aminoxime single-photon emission computed tomography prediction of conversion from mild cognitive impairment to Alzheimer disease. Am J Geriatr Psychiatry (2010) 0.83
Surface feature-guided mapping of cerebral metabolic changes in cognitively normal and mildly impaired elderly. Mol Imaging Biol (2009) 0.83
Imaging the Alzheimer brain. J Alzheimers Dis (2011) 0.83
Dementia syndromes: evaluation and treatment. Expert Rev Neurother (2007) 0.83
Assessing the reliability to detect cerebral hypometabolism in probable Alzheimer's disease and amnestic mild cognitive impairment. J Neurosci Methods (2010) 0.82
Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study. Am J Geriatr Psychiatry (2008) 0.82
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
Quantum dots for live cells, in vivo imaging, and diagnostics. Science (2005) 21.62
Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci (1986) 18.17
Distributed and overlapping representations of faces and objects in ventral temporal cortex. Science (2001) 17.40
Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology (1993) 16.92
The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry (1982) 10.83
MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol (1987) 8.48
Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature (1992) 8.16
Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 7.68
Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 7.51
Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology (2009) 7.04
Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol (1991) 7.01
Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med (2000) 6.72
Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci (2000) 6.54
Differential regulation and properties of MAPKs. Oncogene (2007) 6.36
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain (2008) 6.29
Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol (1979) 5.83
Neuron activity related to short-term memory. Science (1971) 5.76
Comparing predictors of conversion and decline in mild cognitive impairment. Neurology (2010) 5.69
Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry (2001) 5.12
Positron emission tomography study of human brain functional development. Ann Neurol (1987) 4.89
Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2000) 4.85
Some relations between changes in the linear electrical properties of striated muscle fibers and changes in ultrastructure. J Gen Physiol (1967) 4.53
Phosphatidylinositol 4,5-bisphosphate functions as a second messenger that regulates cytoskeleton-plasma membrane adhesion. Cell (2000) 4.45
Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc Natl Acad Sci U S A (2001) 4.41
A tabulated summary of the FDG PET literature. J Nucl Med (2001) 4.37
APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study. Neurology (1999) 4.37
Anesthesiologist direction and patient outcomes. Anesthesiology (2000) 4.31
Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 4.26
The role of the anterior prefrontal cortex in human cognition. Nature (1999) 4.25
Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA (1995) 4.02
Direct text entry in electronic progress notes. An evaluation of input errors. Methods Inf Med (2003) 4.00
Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. JAMA (1997) 4.00
Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology (2007) 3.97
The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism of glucose in 51 healthy adults. Neurology (1995) 3.95
GPCRDB: an information system for G protein-coupled receptors. Nucleic Acids Res (1998) 3.94
The functional organization of human extrastriate cortex: a PET-rCBF study of selective attention to faces and locations. J Neurosci (1994) 3.93
Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage (2002) 3.88
Neural activity related to drug craving in cocaine addiction. Arch Gen Psychiatry (2001) 3.84
Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 3.77
Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 3.74
Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer disease. Neurology (2007) 3.71
Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature (1994) 3.70
Method for quantification of brain, ventricular, and subarachnoid CSF volumes from MR images. J Comput Assist Tomogr (1992) 3.62
Documented head injury in early adulthood and risk of Alzheimer's disease and other dementias. Neurology (2000) 3.61
Specificity, sensitivity, and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. Lancet (1996) 3.58
A large-scale insertional mutagenesis screen in zebrafish. Genes Dev (1999) 3.57
Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology (2008) 3.54
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience (2000) 3.40
Role of the posterior parietal cortex in updating reaching movements to a visual target. Nat Neurosci (1999) 3.39
Manganism and idiopathic parkinsonism: similarities and differences. Neurology (1994) 3.34
Performance evaluation of microPET: a high-resolution lutetium oxyorthosilicate PET scanner for animal imaging. J Nucl Med (1999) 3.31
A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci U S A (2000) 3.28
Distinguishing between mechanisms of eukaryotic transcriptional activation with bacteriophage T7 RNA polymerase. Cell (1987) 3.26
Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging (2001) 3.25
Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med (2001) 3.24
A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc (2001) 3.20
Quantitation in positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr (1979) 3.18
Dissociation of object and spatial visual processing pathways in human extrastriate cortex. Proc Natl Acad Sci U S A (1991) 3.15
Noninvasive imaging of protein-protein interactions in living subjects by using reporter protein complementation and reconstitution strategies. Proc Natl Acad Sci U S A (2002) 3.15
Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol (1980) 3.12
Noninvasive molecular imaging of small living subjects using Raman spectroscopy. Proc Natl Acad Sci U S A (2008) 3.06
Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability. Arch Neurol (2000) 3.05
Human pharmacokinetic and dosimetry studies of [(18)F]FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression. J Nucl Med (2001) 3.03
Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging (2005) 3.00
Neuropathologic substrates of ischemic vascular dementia. J Neuropathol Exp Neurol (2000) 2.99
The spectrum of behavioral changes in Alzheimer's disease. Neurology (1996) 2.97
Noninvasive optical imaging of firefly luciferase reporter gene expression in skeletal muscles of living mice. Mol Ther (2001) 2.96
Age-related changes in cortical blood flow activation during visual processing of faces and location. J Neurosci (1994) 2.92
Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol (1998) 2.92
Longitudinal volumetric MRI change and rate of cognitive decline. Neurology (2005) 2.90
Consensus statement on the upcoming crisis in geriatric mental health: research agenda for the next 2 decades. Arch Gen Psychiatry (1999) 2.89
Cortical change in Alzheimer's disease detected with a disease-specific population-based brain atlas. Cereb Cortex (2001) 2.88
Yeast mRNA initiation sites are determined primarily by specific sequences, not by the distance from the TATA element. EMBO J (1985) 2.87
Intranasal lidocaine for treatment of migraine: a randomized, double-blind, controlled trial. JAMA (1996) 2.83
Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology (2008) 2.80
Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer's disease. Neurobiol Aging (2000) 2.80
The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. Mol Psychiatry (2006) 2.80
Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA (2001) 2.79
White matter lesions impair frontal lobe function regardless of their location. Neurology (2004) 2.77
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol (1998) 2.77
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry (2001) 2.74
Hippocampal and cortical atrophy predict dementia in subcortical ischemic vascular disease. Neurology (2000) 2.73
Monitoring protein-protein interactions using split synthetic renilla luciferase protein-fragment-assisted complementation. Anal Chem (2003) 2.72
Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. Proc Natl Acad Sci U S A (1999) 2.71
Critical care transport: outcome evaluation after interfacility transfer and hospitalization. Ann Emerg Med (1999) 2.71
FDG PET imaging in patients with pathologically verified dementia. J Nucl Med (2000) 2.70
Cerebral hyperglycolysis following severe traumatic brain injury in humans: a positron emission tomography study. J Neurosurg (1997) 2.68
Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch Gen Psychiatry (2001) 2.67
Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry (1989) 2.67
Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc Natl Acad Sci U S A (1991) 2.67